Trial Profile
A first-in-human, safety and tolerability study of intranasal formulation of BHV-3500
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man
- 21 Sep 2018 New trial record
- 12 Sep 2018 According to a Biohaven Pharmaceutical media release, the company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the safety and tolerability of BHV-3500.